alexa Battling the Methicillin-Resistant Staphylococcus aureu
ISSN: 1948-5948

Journal of Microbial & Biochemical Technology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Battling the Methicillin-Resistant Staphylococcus aureus Biofilm Challenge with Vancoplus

Manu Chaudhary and Anurag Payasi*

Venus Medicine Research Centre, Hill Top Industrial Estate, Bhatoli Kalan, Baddi, H.P.-173205 India

*Corresponding Author:
Dr. Anurag Payasi
Venus Medicine Research Centre,Hill Top Industrial Estate
Bhatoli, Kalan, Baddi, H.P. - 173205 India
Tel: 91-1795-302072
Fax: 91-1795-302133
E-mail: [email protected]

Received Date: September 12, 2014; Accepted Date: October 17, 2014; Published Date: October 24, 2014

Citation: Chaudhary M, Payasi A (2014) Battling the Methicillin-Resistant Staphylococcus aureus Biofilm Challenge with Vancoplus. J Microb Biochem Technol S10:001. doi: 10.4172/1948-5948.S10-001

Copyright: 2014 Chaudhary M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

The present study was conducted with the aim to find the prevalence of biofilm formation ability among methicillin resistant Staphylococcus aureus (MRSA) isolates and to assess the activities of commonly used drugs against biofilm producing MRSA. Evaluation of prevalence of genes involved in MRSA biofilm production and their gene expression was also studied. Of 55 MRSA, 47 isolates were biofilm producers and 8 isolates were non-biofilm producers. Of 47 biofilm producers, 24 (51.0%), 14 (29.8%) and 9 (19.1%) produced strong (OD570 ≥ 0.5), medium (OD570 ≥ 0.2 to <0.5), weak (OD570 0 to <0.2) biofilm, respectively. Of the 47 isolates, eight determinants (genes) (eno, hla, hlb, clfA, fnaA, icaA, agrII and sar) were found predominantly among 70 to 80% isolates whereas cna was observed only in 21.3%, finbB in 10.6% and ebps in 32% isolates. Amongst the strong biofilm producers (51%), the lowest MIC values obtained with Vancoplus (2-4 μg/ml) >linezolid (128 to 256 μg/ml) >daptomycin, clindamycin and teicoplanin (256 to 512 μg/ml). Biofilms eradication rate was also observed in the same order with Vancoplus (87%) >linezolid (51.8%) >clindamycin (31.9%) >daptomycin (27.5%) >teicoplanin (26.5%). Our results showed that the percentage of finbA, hla, eno, clfA and fib genes expressions down-regulation after Vancoplus treatment was 64.0 ± 5.9, 63.8 ± 5.8, 73.0 ± 7.4, 72.8 ± 7.8 and 71.9 ± 7.8%, respectively as compared to the control among strong biofilm producing MRSA whereas teicoplanin produced only 30.3 ± 2.7 to 34.5 ± 3.8% down regulation in fnbA, hla, eno, clfA and fib genes expression. The other comparator drugs, vancomycin, linezolid and daptomycin, demonstrated variable effects on these genes varying from 4.9 ± 3.9 to 30.3 ± 2.7%. Our data showed that Vancoplus has significantly enhanced activity against MRSA biofilm producing isolates as compared to other drugs. Therefore, use of this antibiotic should be considered to treat the infections caused by biofilm producing MRSA.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords